10.67
price down icon0.56%   -0.06
after-market アフターアワーズ: 10.78 0.11 +1.03%
loading
前日終値:
$10.73
開ける:
$10.99
24時間の取引高:
2.88M
Relative Volume:
0.43
時価総額:
$1.49B
収益:
$67.67M
当期純損益:
$-412.69M
株価収益率:
-2.7884
EPS:
-3.8266
ネットキャッシュフロー:
$-395.87M
1週間 パフォーマンス:
-2.29%
1か月 パフォーマンス:
-36.03%
6か月 パフォーマンス:
-28.05%
1年 パフォーマンス:
-21.52%
1日の値動き範囲:
Value
$10.63
$11.31
1週間の範囲:
Value
$10.63
$11.56
52週間の値動き範囲:
Value
$7.95
$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1074)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
377
Name
Twitter
@intelliatweets
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, RVMD, ALNY

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NTLA icon
NTLA
Intellia Therapeutics Inc
10.67 1.50B 67.67M -412.69M -395.87M -3.8266
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
479.00 121.16B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
667.17 68.78B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
888.82 57.44B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
188.07 40.23B 742.00K -1.37B -1.07B -7.0731
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
278.40 36.28B 4.29B 577.22M 641.34M 4.2086

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-02 アップグレード William Blair Mkt Perform → Outperform
2025-11-12 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-11 ダウングレード Evercore ISI Outperform → In-line
2025-11-07 ダウングレード JP Morgan Neutral → Underweight
2025-10-28 ダウングレード Bernstein Outperform → Mkt Perform
2025-10-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-10-27 ダウングレード Guggenheim Buy → Neutral
2025-10-27 ダウングレード William Blair Outperform → Mkt Perform
2025-10-06 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
Jul 25, 2026

NTLA|Intellia Therapeutics Inc|Price:10.730|Chg%:-0.370 - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Intellia Therapeutics CFO sells $91,248 in stock By Investing.com - Investing.com UK

Jul 25, 2026
pulisher
Jul 25, 2026

NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits

Jul 25, 2026
pulisher
Jul 25, 2026

Form 4 Intellia Therapeutics Inc For: 24 July By Investing.com - Investing.com Nigeria

Jul 25, 2026
pulisher
Jul 24, 2026

Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dulac Edward J III - Moomoo

Jul 24, 2026
pulisher
Jul 24, 2026

Intellia Therapeutics CFO sells $91,248 in stock - Investing.com

Jul 24, 2026
pulisher
Jul 24, 2026

Intellia Therapeutics (NTLA) CFO logs 8,111-share sell-to-cover tax trade - Stock Titan

Jul 24, 2026
pulisher
Jul 24, 2026

Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout | AI

Jul 24, 2026
pulisher
Jul 24, 2026

Intellia Therapeutics Inc (NTLA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 24, 2026
pulisher
Jul 22, 2026

More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits

Jul 22, 2026
pulisher
Jul 21, 2026

Intellia Therapeutics Stock Short Interest Falls to 44.41% - Quiver Quantitative

Jul 21, 2026
pulisher
Jul 21, 2026

Intellia Stock And 2 Growth Shares With Clear Earnings Upside - simplywall.st

Jul 21, 2026
pulisher
Jul 20, 2026

(NTLA) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Jul 20, 2026
pulisher
Jul 19, 2026

Intellia Therapeutics (NTLA) Income Statement & Earnings - Moomoo

Jul 19, 2026
pulisher
Jul 18, 2026

NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits

Jul 18, 2026
pulisher
Jul 17, 2026

Intellia Therapeutics (NTLA) Dips 4% as Gene Editing Stock Faces Support Test Near $10.81Put Dominated - dars.gov.et

Jul 17, 2026
pulisher
Jul 17, 2026

Intellia Therapeutics (NTLA) Resumes Key Trials, Is The Undervalued Case Still Convincing? - Sahm

Jul 17, 2026
pulisher
Jul 16, 2026

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits

Jul 16, 2026
pulisher
Jul 16, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA) - The Globe and Mail

Jul 16, 2026
pulisher
Jul 16, 2026

NTLA Downgraded by Wolfe Research -- Rating Changed to Underperf - GuruFocus

Jul 16, 2026
pulisher
Jul 16, 2026

Intellia Therapeutics stock trades below recent highs as gene-editing pipeline progresses after late - ad-hoc-news.de

Jul 16, 2026
pulisher
Jul 16, 2026

NTLA Downgraded by Wolfe Research -- Rating Changed to Underperform - GuruFocus

Jul 16, 2026
pulisher
Jul 16, 2026

This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga

Jul 16, 2026
pulisher
Jul 16, 2026

Intellia stock downgraded by Wolfe Research on valuation concerns - Investing.com

Jul 16, 2026
pulisher
Jul 14, 2026

Intellia Therapeutics: An Overvalued Biotech With Little To No Commercial Potential (NTLA) - Seeking Alpha

Jul 14, 2026
pulisher
Jul 14, 2026

4 Best CRISPR Companies to Buy in 2026 and How to Invest - The Motley Fool

Jul 14, 2026
pulisher
Jul 11, 2026

Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch PlansWhat's Changed - Sahm

Jul 11, 2026
pulisher
Jul 10, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 10, 2026
pulisher
Jul 10, 2026

Intellia Therapeutics (NTLA) Could Be 37% Below Fair Value On Gene Editing Hopes - Sahm

Jul 10, 2026
pulisher
Jul 10, 2026

NTLA Maintained by Wedbush -- Price Target Raised to $17.00 - GuruFocus

Jul 10, 2026
pulisher
Jul 10, 2026

Intellia Therapeutics (NTLA) BofA Securities 2025 Healthcare Conference Summary - Quartr

Jul 10, 2026
pulisher
Jul 10, 2026

NTLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Jul 10, 2026
pulisher
Jul 10, 2026

Intellia Therapeutics (NTLA) Short Interest & Short Float | Updated Jul 2026 $NTLA - MarketBeat

Jul 10, 2026
pulisher
Jul 09, 2026

Intellia Therapeutics Inc. (NTLA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com

Jul 09, 2026
pulisher
Jul 09, 2026

Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success - Yahoo Finance

Jul 09, 2026
pulisher
Jul 09, 2026

Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating - Moomoo

Jul 09, 2026
pulisher
Jul 09, 2026

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? - Yahoo Finance

Jul 09, 2026
pulisher
Jul 09, 2026

Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns - Yahoo Finance

Jul 09, 2026
pulisher
Jul 09, 2026

NTLA Stock Price Prediction 2025-2026 | Intellia Therapeutics Inc Forecast - 24/7 Wall St.

Jul 09, 2026

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$91.09
price up icon 1.97%
$118.87
price up icon 1.02%
$34.72
price down icon 0.83%
$58.73
price down icon 0.17%
ONC ONC
$325.90
price up icon 0.00%
$278.40
price up icon 2.44%
大文字化:     |  ボリューム (24 時間):